

**EXPRESS MAIL NO.: EV 335 856 729 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: DING *et al.*

Confirmation No.: To be assigned

Application No.: To be assigned  
(continuation of U.S. Application No.  
09/942,716 filed August 30, 2001)

Art Unit: To be assigned

Filed: Herewith

Examiner: To be assigned

For: DRUG COATING WITH TOPCOAT Attorney Docket No.: 10177-191-999

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references **AA-FE**, which are listed on the attached revised PTO Form 1449. Copies of these references are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith several pages of a "revised form PTO 1449" entitled "List of References Cited by Applicant" instead of "List of Prior Art Cited."


Pursuant to 37 C.F.R. §1.97(b), since this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits, it is believed that no fee is due on connection herewith. However, should the Patent and Trademark Office determine

otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Respectfully submitted,

Date: June 24, 2003

  
Gidon D. Stern

27,469  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036  
(212) 790-9090

<b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO
		10177-191	To be assigned
		APPLICANT	Ding <i>et al.</i>
FILING DATE	GROUP		
June 24, 2003	To be assigned		

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	6,198,016	3/06/01	Lucast et al			
AB	6,110,483	9/29/00	Whitbourne et al.			
AC	6,099,562	8/08/00	Ding et al			
AD	6,096,070	08/01/00	Ragheb et al			
AE	6,042,875	3/28/00	Ding et al.			
AF	5,980,972	11/09/99	Ding			
AG	5,900,246	5/04/99	Lambert			
AH	5,849,034	12/15/98	Schwartz			
AI	5,824,054	10/20/98	Khosravi et al			
AJ	5,824,048	10/20/98	Tuch			
AK	5,800,507	9/01/98	Schwartz			
AL	5,779,732	7/14/98	Amundson			
AM	5,776,184	7/07/98	Tuch			
AN	5,749,915	5/12/98	Slepiant			
AO	5,735,897	4/07/98	Buirge			
AP	5,716,981	2/10/98	Hunter et al.			
AQ	5,700,559	12/23/97	Sheu et al			
AR	5,697,967	12/16/97	Dinh et al.			
AS	5,688,855	11/18/97	Stoy et al.			
AT	5,679,400	10/21/97	Tuch			
AU	5,662,712	9/02/97	Pathak et al.			
AV	5,643,580	7/01/97	Subramanian			
AW	5,637,113	6/10/97	Tartaglia et al.			
AX	5,632,840	5/27/97	Campbell			
AY	5,629,077	5/13/97	Turnlund et al			
AZ	5,624,411	04/29/97	Tuch			
BA	5,605,696	2/25/97	Eury et al.			
BB	5,591,227	1/07/97	Dinh et al			
BC	5,591,224	1/07/97	Schwartz et al			
BD	5,578,075	11/26/96	Dayton			
BE	5,551,954	9/03/96	Buscemi et al.			
BF	5,545,208	8/13/96	Wolff et al			
BG	5,534,155	8/06/96	Fekete et al			
BH	5,512,055	4/30/96	Domb et al			
BI	5,500,013	3/19/96	Buschemi et al			

	BJ	5,496,557	3/05/96	Feijen et al			
	BK	5,486,357	1/23/96	Narayanan			
	BL	5,474,563	12/12/95	Myler et al			
	BM	5,464,650	11/7/95	Berg et al.			
	BN	5,449,382	9/12/95	Dayton			
	BO	5,447,724	9/5/95	Helmus et al.			
	BP	5,429,618	7/4/95	Keogh			
	BQ	5,419,760	5/30/95	Narciso, Jr.			
	BR	5,415,619	5/16/95	Lee et al.			
	BS	5,391,378	2/21/95	Sanderson			
	BT	5,380,299	01/10/95	Fearnott et al.			
	BU	5,356,433	10/18/94	Rowland et al.			
	BV	5,342,348	8/30/94	Kaplan			
	BW	5,338,770	8/16/94	Winters et al.			
	BX	5,318,779	6/07/94	Hakamatsuka et a			
	BY	5,308,889	5/03/94	Rhee et al.			
	BZ	5,304,121	4/19/94	Sahatjian			
	CA	5,292,802	3/8/94	Rhee et al.			
	CB	5,282,823	2/01/94	Schwartz et al.			
	CC	5,262,451	11/16/93	Winters et al.			
	CD	5,258,020	11/02/93	Froix			
	CE	5,226,913	7/13/93	Pinchuk			
	CF	5,222,971	6/29/93	Willard et al			
	CG	5,185,408	2/09/93	Tang et al.			
	CH	5,182,317	1/26/93	Winters et al.			
	CI	5,180,376	1/19/93	Fischell			
	CJ	5,180,366	1/19/93	Woods			
	CK	5,163,952	11/17/92	Froix			
	CL	5,102,417	4/07/92	Palmaz			
	CM	5,092,877	3/3/92	Pinchuk			
	CN	5,064,435	11/12/91	Porter			
	CO	5,061,275	10/29/91	Wallsten et al.			
	CP	5,059,166	10/22/91	Fischell et al.			
	CQ	5,053,048	10/01/91	Pinchuk			
	CR	5,019,096	5/28/91	Fox Jr. et al			
	CS	4,994,071	2/19/91	McGregor			
	CT	4,990,158	2/05/91	Kaplan et al			
	CU	4,954,126	9/4/90	Wallsten			

	CV	4,922,905	5/08/90	Strecker			
	CW	4,916,193	4/10/90	Tang et al.			
	CX	4,886,062	12/12/89	Wiktor			
	CY	4,872,867	10/10/89	Joh et al			
	CZ	4,776,337	10/11/88	Palmaz			
	DA	4,768,507	9/06/88	Fischell et al			
	DB	4,739,762	4/26/88	Palmaz			
	DC	4,689,046	8/25/87	Bokros			
	DD	4,678,466	7/07/87	Rosenwald			
	DE	4,655,771	4/07/87	Wallsten			
	DF	4,613,665	9/23/86	Larm			
	DG	4,300,244	11/17/81	Bokros			
	DH	4,292,965	10/06/81	Nash et al.			
	DI	4,219,520	8/26/80	Kline			
	DJ	3,952,334	4/27/76	Bokros et al			
	DK	3,932,627	01/13/76	Margaf			
	DL	3,879,516	4/22/75	Wolvek			
	DM	3,738,365	6/12/73	Schulte			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
	DN	CA 2,207,659 ✓	06/13/96	Canada			
	DO	DE A 3 918 736 ✓	10/90	Germany (with English lang, abstract)			
	DP	DE A 40 22 956 ✓	12/69	Germany (with English lang, abstract)			
	DQ	EP 0 604 022 A1 ✓	11/24/93	EPO			
	DR	EP 0 621 015 ✓	04/23/04	EPO			
	DS	EP A 0 430 542 ✓	11/20/90	EPO			
	DT	EP A 0 435 518 ✓	12/13/90	EPO			
	DU	EP A 0 623 345 ✓	05/03/94	EPO			
	DV	EP 0 716 836 A1 ✓	12/11/95	EPO			
	DW	EP 0 734 721 A2 ✓	03/20/96	EPO			
	DX	GB A 1 205 743 ✓	07/15/96	London			
	DY	GB A 2 153 253 ✓	1/25/85	UK			
	DZ	PCT/IB 96/00272 ✓	06/26/96	PCT			
	EA	WO 89/03232 ✓	04/20/89	PCT			
	EB	WO 90/13332 ✓	11/15/90	PCT			
	EC	WO 91/12779 ✓	09/05/91	PCT			
	ED	WO 92/15286 ✓	09/17/92	PCT			
	EE	WO 94/01056 ✓	1/20/94	PCT			
	EF	WO 94/24961 ✓	11/10/94	PCT			
	EG	WO 94/21308 ✓	09/29/94	PCT/US94/02488			

	EH	WO 94/21309	✓	09/29/94	PCT/BE94/00024				
	EI	WO 96/32907	✓	10/24/96	PCT				
	EJ	WO 97/10011	✓	03/20/97	PCT				
	EK	08-33718	✓	02/06/96	Japan (with English lang, abstract)				
	EL	06-121828	✓	06/05/94	Japan (with English lang, abstract)				
	EM	03-297469	✓	12/27/91	Japan (with English lang, abstract)				
	EN	06-205838	✓	07/26/94	Japan (with English lang, abstract)				

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

EO	Bergstrom, Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces, 1992, p. 779-790, Baxter Healthcare Corp. Duraflow Biocompatible Treatment	✓
EP	Michael N. Helmus, "Medical Device Design--A Systems Approach: Central Venous Catheters", (1990)	✓
EQ	Polysciences Inc., TDMAC-Heparin Coatings, Nov. 1988, Data Sheet #172	✓
ER	Barbucci, et al., Coating of Commercially available materials with a new heparinizable material, 1991, pp. 1259-1274	✓
ES	Michael N. Helmus, Grant Application-Ionic-Hydrophilic Density: Platelet/Monocyte Adherence 12/81 12/84, pp. 13, 14, 26-31	✓
ET	Dennis E. Chenoweth, Complement Activation in Extracorporeal Circuits, pp. 306-329	✓
EU	Jeffrey A. Hubbell, Ph.D., July-Sept. 1993 Pharmacologic Modification of Materials, 1215-1275	✓
EV	Glenn P. Gradlee, MD, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, April 1994, pp. 213-222	✓
EW	K. Isihara, H. Hanyuda, and N. Nakabayashi, Synthesis of phospholipid polymers having a urethane bond..., Biomaterials, 1995, pp. 873-879	✓
EX	J. Sanchez, G. Elgue, J. Riesenfeld and P. Olsson, Control of Contact activation on end-point immobilized heparin, The role of antithrombin and the specific antithrombin-binding sequence, 1995, pp. 655-661, Journal of Biomedical Materials Research	✓
EY	Cardiology Conference European Society of Cardiology Conference Clinica, Sept. 4, 1995, pp. 24-26	✓
EZ	Baxter Healthcare Corp. Duroflow Biocompatible Treatment	✓
FA	Ludwig K. von Segesser, MD., "Heparin-Bonded Surfaces in Extracorporeal Membrane Oxygenation for Cardiac Support; The Society of Thoracic Surgeons, (1996)	✓
FB	Li-Chien Hsu, "Principles of Heparin-Coating Techniques", Perfusion 6: 209-219 (1991)	✓
FC	J.M. Toomasian et al., "Evaluation of Duraflow II Heparin Coating in Prolonged Extracorporeal Membrane Oxygenation", ASAIO Trans 34: 410-14 (1988)	✓
FD	S.D. Tong et al., "Non-Thrombogenic Hemofiltration System for Acute renal failure Treatment: ASAIO Trans. 38: M702-M706 (1992)	✓
FE	Mansoor Amiji and Kinam Park, "Surface Modification of Polymeric Materials with Poly (ethylene oxide), Albumin, and Heparin For Reduced Thrombogenicity," Purdue University, School of Pharmacy, West Lafayette, IN 47907	✓

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.